Yıl: 2021 Cilt: 47 Sayı: 2 Sayfa Aralığı: 120 - 124 Metin Dili: İngilizce DOI: 10.5152/tud.2021.20341 İndeks Tarihi: 23-05-2022

Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer

Öz:
Objective: This pilot study aimed to objectively assess the osteoporotic effect caused by androgen deprivation therapy (ADT) in patients with prostate cancer and compare this effect in surgical versus medical castration, specifically with luteinizing hormone-releasing hormone (LHRH) antagonists. Material and methods: The study included 60 patients with metastatic prostate adenocarcinoma treated with either bilateral orchidectomy (group I) or LHRH antagonist (Degarelix) injection (group II). The patients had a baseline bone mineral density (BMD) assessment before the start of ADT using dual energy X-ray absorptiometry (DEXA) scan and then follow-up assessment after 6 months. BMD was measured at the spine (lumbar vertebrae L2–L4), femur (total), and forearm (one-third radius). Results: Group I included 33 patients and group II 27 patients. Both the groups showed significant reduction in BMD at the spine and femur after 6 months, whereas the forearm did not show a significant reduction. Spine BMD showed 5.9%±2.6% and 4.7%±2.6% reduction whereas the femur BMD showed 6%±7.4% and 6%±4.7% reduction in the orchiectomy and the Degarelix groups, respectively. There was no statistically significant difference between the groups at the 3 measured sites. Conclusion: Both surgical castration and LHRH antagonists were associated with significant accelerated osteoporotic effect at the spine and femur after 6 months without difference between both the methods. Assessment of osteoporotic risk together with preventive or management measures should be started early during ADT.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. [Crossref]
  • 2. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017;71:630-42. [Crossref]
  • 3. Zitzmann M, Nieschlag E. Androgens and bone metabolism. In: Nieschlag E, Behre HM (Eds): Testosterone: Action, Deficiency, Subsitution. Third Edition Cambrigde University Press. 2004; 233-54. [Crossref]
  • 4. Kasperk CH, Wakley GK, Hierl T, Ziegler R. Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. J Bone Miner Res 1997;12:464-71. [Crossref]
  • 5. Chen Q, Kaji H, Sugimoto T, Chihara K. Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. FEBS Lett 2001;491:91-3. [Crossref]
  • 6. Poulsen MH, Frost M, Abrahamsen B, Gerke O, Walter S, Lund L. Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy. Scand J Urol 2019;53:34-9. [Crossref]
  • 7. Ahlborg HG, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Incidence and risk factors for low trauma fractures in men with prostate cancer. Bone 2008;43:556-60. [Crossref]
  • 8. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hu Pathol 2000;31:578-83. [Crossref]
  • 9. Inoue T, Segawa T, Kamba T, Yoshimura K, Nakamura E, Nishiyama H, et al. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology 2009;73:1104-9. [Crossref]
  • 10. Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol 2004;46:731-9. [Crossref]
  • 11. Fogelman I, Blake GM. Different approaches to bone densitometry. J Nucl Med 2000;41:2015-25.
  • 12. Koval PG, Easterling L, Pettus D, Mackler L, Gottschall AB. Clinical inquiries: How should a DEXA scan be used to evaluate bisphosphonate therapy for osteoporosis? J Fam Pract 2005;54:65-71.
  • 13. Rachner TD, Coleman R, Hadji P, Hofbauer LC. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol 2018;6:901-10 [Crossref]
  • 14. Kirk PS, Borza T, Shahinian VB, Caram MEV, Makarov DV, Shelton JB, et al. The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer. BJU Int 2018;121:558-64. [Crossref]
  • 15. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001;57:127-32. [Crossref]
  • 16. Jia-Qi Y, Tao X, Xiao-Wei Z, Wang XF. Metabolic complications and quality of life in prostate cancer patients after receiving endocrine treatment. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2013;35:88-94.
  • 17. Vargas A, Machado RD, Filho DL, Paiva CE, Dos Reis RB, Tobias-Machado M, et al. LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer. World J Urol 2016;34:1621-8. [Crossref]
  • 18. Reis C, Liberman S, Pompeo AC, Srougi M, Halpern A, Filho WJ. Body composition alterations, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre and post orchiectomy. Clinics (Sao Paulo) 2009;64:781-4. [Crossref]
  • 19. Lee H, McGovern K, Finkelstein JS. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005;104:1633-7. [Crossref]
  • 20. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001;86:2787-91. [Crossref]
  • 21. Yaturu S, Djedjos S, Alferos G, Deprisco C. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy. Prostate Cancer Prostatic Dis 2006;9:35-8. [Crossref]
  • 22. Sun M, Choueiri T, Hamnvik O, Preston MA, De Velasco G, Jiang W, et al. Comparison of Gonadotropin-Releasing Hormone agonists and Orchiectomy. JAMA Oncol 2016;2:500-7. [Crossref]
  • 23. Van Asseldonk B, Black P, Elterman DS. Chemical vs surgical ADT in metastatic prostate cancer: a comparison of side effects. Commentary on comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen deprivation therapy. Urology 2016;93:3-4. [Crossref]
APA sharafeldeen m, Elsaqa M, Sameh W, elabbady a (2021). Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer. , 120 - 124. 10.5152/tud.2021.20341
Chicago sharafeldeen mohamed,Elsaqa Mohamed,Sameh Wael,elabbady ahmed Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer. (2021): 120 - 124. 10.5152/tud.2021.20341
MLA sharafeldeen mohamed,Elsaqa Mohamed,Sameh Wael,elabbady ahmed Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer. , 2021, ss.120 - 124. 10.5152/tud.2021.20341
AMA sharafeldeen m,Elsaqa M,Sameh W,elabbady a Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer. . 2021; 120 - 124. 10.5152/tud.2021.20341
Vancouver sharafeldeen m,Elsaqa M,Sameh W,elabbady a Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer. . 2021; 120 - 124. 10.5152/tud.2021.20341
IEEE sharafeldeen m,Elsaqa M,Sameh W,elabbady a "Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer." , ss.120 - 124, 2021. 10.5152/tud.2021.20341
ISNAD sharafeldeen, mohamed vd. "Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer". (2021), 120-124. https://doi.org/10.5152/tud.2021.20341
APA sharafeldeen m, Elsaqa M, Sameh W, elabbady a (2021). Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer. Turkish Journal of Urology, 47(2), 120 - 124. 10.5152/tud.2021.20341
Chicago sharafeldeen mohamed,Elsaqa Mohamed,Sameh Wael,elabbady ahmed Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer. Turkish Journal of Urology 47, no.2 (2021): 120 - 124. 10.5152/tud.2021.20341
MLA sharafeldeen mohamed,Elsaqa Mohamed,Sameh Wael,elabbady ahmed Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer. Turkish Journal of Urology, vol.47, no.2, 2021, ss.120 - 124. 10.5152/tud.2021.20341
AMA sharafeldeen m,Elsaqa M,Sameh W,elabbady a Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer. Turkish Journal of Urology. 2021; 47(2): 120 - 124. 10.5152/tud.2021.20341
Vancouver sharafeldeen m,Elsaqa M,Sameh W,elabbady a Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer. Turkish Journal of Urology. 2021; 47(2): 120 - 124. 10.5152/tud.2021.20341
IEEE sharafeldeen m,Elsaqa M,Sameh W,elabbady a "Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer." Turkish Journal of Urology, 47, ss.120 - 124, 2021. 10.5152/tud.2021.20341
ISNAD sharafeldeen, mohamed vd. "Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer". Turkish Journal of Urology 47/2 (2021), 120-124. https://doi.org/10.5152/tud.2021.20341